The US Supreme Court denied Agilent Technologies’ request to review invalidation of CRISPR-related patents tied to guide RNA chemical modifications, according to reporting grounded in a Synthego statement. The denial leaves intact a Federal Circuit ruling that had upheld PTAB decisions deeming the claims unpatentable. The dispute traces to attempts by Agilent to license or enforce specific gRNA modifications after Synthego preemptively sued for non-infringement. Supreme Court rejection effectively ends the multi-year appellate pathway. For gene-editing developers, the practical impact is the removal of a claimed barrier to using certain gRNA modifications in CRISPR-enabled research and potential therapeutics, shifting the patent landscape around tooling. The case also signals the durability of USPTO PTAB decisions when challengers reach higher courts—an issue that continues to shape investment and platform IP strategies across the gene editing ecosystem.